• Oculis Holding AG has completed final patient visits in both Phase 3 DIAMOND trials of OCS-01, a topical eye drop for diabetic macular edema, with topline results from over 800 patients expected by June 2026 and a potential NDA filing targeted for the Fourth Quarter of 2026.
• The program aims to introduce the first non-invasive DME therapy, addressing a large population of untreated or inadequately treated patients who currently rely on injection-based options.
• With shares rising over the past week, we will examine how progress toward a potential first-in-class topical DME treatment shapes Oculis’ investment narrative.

AI is about to change healthcare. These 35 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

What Is Oculis Holding's Investment Narrative?

To own Oculis here, you really have to believe in OCS-01 as a meaningful new option in diabetic macular edema and, more broadly, in the value of its retina and neuro-ophthalmology pipeline despite minimal current revenue and large ongoing losses. The completion of final patient visits in the DIAMOND Phase 3 program is important because it de-risks execution around the trial timeline and locks in a clearer catalyst path, with topline data and a potential NDA now on the calendar rather than just on slides. The recent share price strength suggests the market is already reacting to that reduced timing risk, even though clinical, regulatory and financing risks remain front and center. In the near term, everything still comes down to Phase 3 outcomes and the company’s ability to fund itself through them.

However, investors also need to be comfortable with continued losses and potential further dilution. Oculis Holding's shares have been on the rise but are still potentially undervalued. Find out how large the opportunity might be.

Exploring Other Perspectives

The single Simply Wall St Community fair value estimate clusters at US$48.07, while recent gains and the DIAMOND Phase 3 timeline keep expectations tightly bound to OCS-01’s trial and financing risk profile.

Explore another fair value estimate on Oculis Holding - why the stock might be worth just $48.07!

Form Your Own Verdict

Disagree with this assessment? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Oculis Holding research is our analysis highlighting 3 key rewards and 3 important warning signs that could impact your investment decision.
• Our free Oculis Holding research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Oculis Holding's overall financial health at a glance.

No Opportunity In Oculis Holding?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 31 best rare earth metal stocks of the very few that mine this essential strategic resource.
• Uncover the next big thing with 26 elite penny stocks that balance risk and reward.
• Capitalize on the AI infrastructure supercycle with our selection of the 39 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.